DDI Drug Name |
DDI Drug ID |
Severity |
Mechanism |
Comorbidity |
REF |
Thioguanine |
DM7NKEV
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Thioguanine. |
Acute myeloid leukaemia [2A60]
|
[7] |
Uracil mustard |
DMHL7OB
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Uracil mustard. |
Acute myeloid leukaemia [2A60]
|
[7] |
Midostaurin |
DMI6E0R
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Midostaurin. |
Acute myeloid leukaemia [2A60]
|
[7] |
Gemtuzumab ozogamicin |
DMJ2O7B
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Gemtuzumab ozogamicin. |
Acute myeloid leukaemia [2A60]
|
[7] |
Idarubicin |
DMM0XGL
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Idarubicin. |
Acute myeloid leukaemia [2A60]
|
[7] |
Daunorubicin |
DMQUSBT
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Daunorubicin. |
Acute myeloid leukaemia [2A60]
|
[7] |
Oliceridine |
DM6MDCF
|
Moderate |
Altered metabolism of Anakinra due to Oliceridine alters the formation of CYP450 enzymes. |
Acute pain [MG31]
|
[6] |
Siltuximab |
DMGEATB
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Siltuximab. |
Anemia [3A00-3A9Z]
|
[7] |
Nifedipine |
DMSVOZT
|
Moderate |
Altered metabolism of Anakinra due to Nifedipine alters the formation of CYP450 enzymes. |
Angina pectoris [BA40]
|
[6] |
Alprazolam |
DMC7XDN
|
Moderate |
Altered metabolism of Anakinra due to Alprazolam alters the formation of CYP450 enzymes. |
Anxiety disorder [6B00-6B0Z]
|
[6] |
Methylphenobarbital |
DMDSWAG
|
Moderate |
Altered metabolism of Anakinra due to Methylphenobarbital alters the formation of CYP450 enzymes. |
Anxiety disorder [6B00-6B0Z]
|
[8] |
Clobazam - Lundbeck |
DMW1OQ0
|
Moderate |
Altered metabolism of Anakinra due to Clobazam - Lundbeck alters the formation of CYP450 enzymes. |
Anxiety disorder [6B00-6B0Z]
|
[6] |
Budesonide |
DMJIBAW
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Budesonide. |
Asthma [CA23]
|
[7] |
Aminophylline |
DML2NIB
|
Moderate |
Altered metabolism of Anakinra due to Aminophylline alters the formation of CYP450 enzymes. |
Asthma [CA23]
|
[6] |
Roflumilast |
DMPGHY8
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Roflumilast. |
Asthma [CA23]
|
[6] |
Dupilumab |
DMOAD2Y
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Dupilumab. |
Atopic eczema [EA80]
|
[7] |
Linezolid |
DMGFPU2
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Linezolid. |
Bacterial infection [1A00-1C4Z]
|
[7] |
Temozolomide |
DMKECZD
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Temozolomide. |
Brain cancer [2A00]
|
[7] |
Lomustine |
DMMWSUL
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Lomustine. |
Brain cancer [2A00]
|
[7] |
Eribulin |
DM1DX4Q
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Eribulin. |
Breast cancer [2C60-2C6Y]
|
[7] |
Talazoparib |
DM1KS78
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Talazoparib. |
Breast cancer [2C60-2C6Y]
|
[7] |
Ixabepilone |
DM2OZ3G
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Ixabepilone. |
Breast cancer [2C60-2C6Y]
|
[7] |
LY2835219 |
DM93VBZ
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and LY2835219. |
Breast cancer [2C60-2C6Y]
|
[7] |
Pralatrexate |
DMAO80I
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Pralatrexate. |
Breast cancer [2C60-2C6Y]
|
[7] |
Palbociclib |
DMD7L94
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Palbociclib. |
Breast cancer [2C60-2C6Y]
|
[7] |
Mitomycin |
DMH0ZJE
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Mitomycin. |
Breast cancer [2C60-2C6Y]
|
[7] |
Thiotepa |
DMIZKOP
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Thiotepa. |
Breast cancer [2C60-2C6Y]
|
[7] |
Cabazitaxel |
DMPAZHC
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Cabazitaxel. |
Breast cancer [2C60-2C6Y]
|
[7] |
Bosutinib |
DMTI8YE
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Bosutinib. |
Breast cancer [2C60-2C6Y]
|
[7] |
Trastuzumab |
DMZQOUX
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Trastuzumab. |
Breast cancer [2C60-2C6Y]
|
[7] |
Atorvastatin |
DMF28YC
|
Moderate |
Altered metabolism of Anakinra due to Atorvastatin alters the formation of CYP450 enzymes. |
Cardiovascular disease [BA00-BE2Z]
|
[6] |
Corticotropin |
DMP9TWZ
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Corticotropin. |
Chronic kidney disease [GB61]
|
[7] |
Irinotecan |
DMP6SC2
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Irinotecan. |
Colorectal cancer [2B91]
|
[7] |
Oxaliplatin |
DMQNWRD
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Oxaliplatin. |
Colorectal cancer [2B91]
|
[7] |
Aflibercept |
DMT3D5I
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Aflibercept. |
Colorectal cancer [2B91]
|
[7] |
Capecitabine |
DMTS85L
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Capecitabine. |
Colorectal cancer [2B91]
|
[7] |
Drospirenone |
DM1A9W3
|
Moderate |
Altered metabolism of Anakinra due to Drospirenone alters the formation of CYP450 enzymes. |
Contraceptive management [QA21]
|
[6] |
Levonorgestrel |
DM1DP7T
|
Moderate |
Altered metabolism of Anakinra due to Levonorgestrel alters the formation of CYP450 enzymes. |
Contraceptive management [QA21]
|
[6] |
Mestranol |
DMG3F94
|
Moderate |
Altered metabolism of Anakinra due to Mestranol alters the formation of CYP450 enzymes. |
Contraceptive management [QA21]
|
[8] |
Etonogestrel |
DMKA8J4
|
Moderate |
Altered metabolism of Anakinra due to Etonogestrel alters the formation of CYP450 enzymes. |
Contraceptive management [QA21]
|
[6] |
Norgestimate |
DMYP4XC
|
Moderate |
Altered metabolism of Anakinra due to Norgestimate alters the formation of CYP450 enzymes. |
Contraceptive management [QA21]
|
[8] |
Lidocaine |
DML4ZOT
|
Moderate |
Altered metabolism of Anakinra due to Lidocaine alters the formation of CYP450 enzymes. |
Corneal disease [9A76-9A78]
|
[6] |
Nimodipine |
DMQ0RKZ
|
Moderate |
Altered metabolism of Anakinra due to Nimodipine alters the formation of CYP450 enzymes. |
Coronary vasospastic disease [BA85]
|
[6] |
Oxtriphylline |
DMLHSE3
|
Moderate |
Altered metabolism of Anakinra due to Oxtriphylline alters the formation of CYP450 enzymes. |
Cough [MD12]
|
[6] |
Methadone |
DMTW6IU
|
Moderate |
Altered metabolism of Anakinra due to Methadone alters the formation of CYP450 enzymes. |
Cough [MD12]
|
[6] |
Mycophenolic acid |
DMRBMAU
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Mycophenolic acid. |
Crohn disease [DD70]
|
[7] |
Rivaroxaban |
DMQMBZ1
|
Moderate |
Altered metabolism of Anakinra due to Rivaroxaban alters the formation of CYP450 enzymes. |
Deep vein thrombosis [BD71]
|
[6] |
Polatuzumab vedotin |
DMF6Y0L
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Polatuzumab vedotin. |
Diffuse large B-cell lymphoma [2A81]
|
[7] |
Axicabtagene ciloleucel |
DMYHN59
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Axicabtagene ciloleucel. |
Diffuse large B-cell lymphoma [2A81]
|
[7] |
PMID28870136-Compound-48 |
DMPIM9L
|
Moderate |
Altered metabolism of Anakinra due to PMID28870136-Compound-48 alters the formation of CYP450 enzymes. |
Discovery agent [N.A.]
|
[6] |
Oestradiol valerate and dienogest |
DMZK0FQ
|
Moderate |
Altered metabolism of Anakinra due to Oestradiol valerate and dienogest alters the formation of CYP450 enzymes. |
Endometriosis [GA10]
|
[8] |
Diazepam |
DM08E9O
|
Moderate |
Altered metabolism of Anakinra due to Diazepam alters the formation of CYP450 enzymes. |
Epilepsy/seizure [8A61-8A6Z]
|
[6] |
Primidone |
DM0WX6I
|
Moderate |
Altered metabolism of Anakinra due to Primidone alters the formation of CYP450 enzymes. |
Epilepsy/seizure [8A61-8A6Z]
|
[6] |
Mephenytoin |
DM5UGDK
|
Moderate |
Altered metabolism of Anakinra due to Mephenytoin alters the formation of CYP450 enzymes. |
Epilepsy/seizure [8A61-8A6Z]
|
[6] |
Ethosuximide |
DMDZ9LT
|
Moderate |
Altered metabolism of Anakinra due to Ethosuximide alters the formation of CYP450 enzymes. |
Epilepsy/seizure [8A61-8A6Z]
|
[6] |
Phenytoin |
DMNOKBV
|
Moderate |
Altered metabolism of Anakinra due to Phenytoin alters the formation of CYP450 enzymes. |
Epilepsy/seizure [8A61-8A6Z]
|
[6] |
Fosphenytoin |
DMOX3LB
|
Moderate |
Altered metabolism of Anakinra due to Fosphenytoin alters the formation of CYP450 enzymes. |
Epilepsy/seizure [8A61-8A6Z]
|
[6] |
Clonazepam |
DMTO13J
|
Moderate |
Altered metabolism of Anakinra due to Clonazepam alters the formation of CYP450 enzymes. |
Epilepsy/seizure [8A61-8A6Z]
|
[6] |
Phenobarbital |
DMXZOCG
|
Moderate |
Altered metabolism of Anakinra due to Phenobarbital alters the formation of CYP450 enzymes. |
Epilepsy/seizure [8A61-8A6Z]
|
[6] |
Carbamazepine |
DMZOLBI
|
Moderate |
Altered metabolism of Anakinra due to Carbamazepine alters the formation of CYP450 enzymes. |
Epilepsy/seizure [8A61-8A6Z]
|
[6] |
Nicardipine |
DMCDYW7
|
Moderate |
Altered metabolism of Anakinra due to Nicardipine alters the formation of CYP450 enzymes. |
Essential hypertension [BA00]
|
[6] |
Bay 80-6946 |
DMLOS5R
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Bay 80-6946. |
Follicular lymphoma [2A80]
|
[7] |
Avapritinib |
DMK2GZX
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Avapritinib. |
Gastrointestinal stromal tumour [2B5B]
|
[7] |
177Lu-DOTATATE |
DMT8GVU
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and 177Lu-DOTATATE. |
Hepatitis virus infection [1E50-1E51]
|
[7] |
Procarbazine |
DMIK367
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Procarbazine. |
Hodgkin lymphoma [2B30]
|
[7] |
Bleomycin |
DMNER5S
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Bleomycin. |
Hodgkin lymphoma [2B30]
|
[7] |
Brentuximab vedotin |
DMWLC57
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Brentuximab vedotin. |
Hodgkin lymphoma [2B30]
|
[7] |
Zidovudine |
DM4KI7O
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Zidovudine. |
Human immunodeficiency virus disease [1C60-1C62]
|
[7] |
Simvastatin |
DM30SGU
|
Moderate |
Altered metabolism of Anakinra due to Simvastatin alters the formation of CYP450 enzymes. |
Hyper-lipoproteinaemia [5C80]
|
[6] |
Lovastatin |
DM9OZWQ
|
Moderate |
Altered metabolism of Anakinra due to Lovastatin alters the formation of CYP450 enzymes. |
Hyper-lipoproteinaemia [5C80]
|
[6] |
Nisoldipine |
DM7ISKJ
|
Moderate |
Altered metabolism of Anakinra due to Nisoldipine alters the formation of CYP450 enzymes. |
Hypertension [BA00-BA04]
|
[6] |
Levamlodipine |
DM92S6N
|
Moderate |
Altered metabolism of Anakinra due to Levamlodipine alters the formation of CYP450 enzymes. |
Hypertension [BA00-BA04]
|
[6] |
Isradipine |
DMA5XGH
|
Moderate |
Altered metabolism of Anakinra due to Isradipine alters the formation of CYP450 enzymes. |
Hypertension [BA00-BA04]
|
[6] |
Amlodipine |
DMBDAZV
|
Moderate |
Altered metabolism of Anakinra due to Amlodipine alters the formation of CYP450 enzymes. |
Hypertension [BA00-BA04]
|
[6] |
Felodipine |
DMOSW35
|
Moderate |
Altered metabolism of Anakinra due to Felodipine alters the formation of CYP450 enzymes. |
Hypertension [BA00-BA04]
|
[6] |
Fludrocortisone |
DMUDIR8
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Fludrocortisone. |
Hypo-osmolality/hyponatraemia [5C72]
|
[7] |
Triazolam |
DMETYK5
|
Moderate |
Altered metabolism of Anakinra due to Triazolam alters the formation of CYP450 enzymes. |
Insomnia [7A00-7A0Z]
|
[6] |
Olaratumab |
DMNYOIX
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Olaratumab. |
Kaposi sarcoma [2B57]
|
[7] |
Methotrexate |
DM2TEOL
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Methotrexate. |
Leukaemia [2A60-2B33]
|
[7] |
Nelarabine |
DMB6VEG
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Nelarabine. |
Leukaemia [2A60-2B33]
|
[7] |
DTI-015 |
DMXZRW0
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and DTI-015. |
Liver cancer [2C12]
|
[7] |
Denosumab |
DMNI0KO
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Denosumab. |
Low bone mass disorder [FB83]
|
[9] |
Brigatinib |
DM7W94S
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Brigatinib. |
Lung cancer [2C25]
|
[7] |
Lurbinectedin |
DMEFRTZ
|
Moderate |
Additive myelosuppressive effects by the combination of Anakinra and Lurbinectedin. |
Lung cancer [2C25]
|
[6] |
Osimertinib |
DMRJLAT
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Osimertinib. |
Lung cancer [2C25]
|
[7] |
Belimumab |
DM3OBQF
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Belimumab. |
Lupus erythematosus [4A40]
|
[7] |
Inotuzumab ozogamicin |
DMAC130
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Inotuzumab ozogamicin. |
Malignant haematopoietic neoplasm [2B33]
|
[7] |
Rituximab |
DM1YVZT
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Rituximab. |
Malignant haematopoietic neoplasm [2B33]
|
[7] |
Tositumomab |
DMMYZ3D
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Tositumomab. |
Malignant haematopoietic neoplasm [2B33]
|
[7] |
Fludarabine |
DMVRLT7
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Fludarabine. |
Malignant haematopoietic neoplasm [2B33]
|
[7] |
Pentostatin |
DM0HXDS
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Pentostatin. |
Mature B-cell leukaemia [2A82]
|
[7] |
Ofatumumab |
DM295PR
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Ofatumumab. |
Mature B-cell leukaemia [2A82]
|
[7] |
Obinutuzumab |
DM3BVAE
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Obinutuzumab. |
Mature B-cell leukaemia [2A82]
|
[7] |
Cladribine |
DM3JDRP
|
Major |
Additive immunosuppressive effects by the combination of Anakinra and Cladribine. |
Mature B-cell leukaemia [2A82]
|
[6] |
Idelalisib |
DM602WT
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Idelalisib. |
Mature B-cell leukaemia [2A82]
|
[7] |
GDC-0199 |
DMH0QKA
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and GDC-0199. |
Mature B-cell leukaemia [2A82]
|
[7] |
Chlorambucil |
DMRKE63
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Chlorambucil. |
Mature B-cell leukaemia [2A82]
|
[7] |
IPI-145 |
DMWA24P
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and IPI-145. |
Mature B-cell leukaemia [2A82]
|
[7] |
Alemtuzumab |
DMZL3IV
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Alemtuzumab. |
Mature B-cell leukaemia [2A82]
|
[10] |
Acalabrutinib |
DM7GCVW
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Acalabrutinib. |
Mature B-cell lymphoma [2A85]
|
[7] |
Clofarabine |
DMCVJ86
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Clofarabine. |
Mature B-cell lymphoma [2A85]
|
[7] |
Blinatumomab |
DMGECIJ
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Blinatumomab. |
Mature B-cell lymphoma [2A85]
|
[7] |
Ibrutinib |
DMHZCPO
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Ibrutinib. |
Mature B-cell lymphoma [2A85]
|
[7] |
Vincristine |
DMINOX3
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Vincristine. |
Mature B-cell lymphoma [2A85]
|
[6] |
Teniposide |
DMLW57T
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Teniposide. |
Mature B-cell lymphoma [2A85]
|
[7] |
Tisagenlecleucel |
DMM9BJD
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Tisagenlecleucel. |
Mature B-cell lymphoma [2A85]
|
[7] |
Mercaptopurine |
DMTM2IK
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Mercaptopurine. |
Mature B-cell lymphoma [2A85]
|
[7] |
Ponatinib |
DMYGJQO
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Ponatinib. |
Mature B-cell lymphoma [2A85]
|
[7] |
Cytarabine |
DMZD5QR
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Cytarabine. |
Mature B-cell lymphoma [2A85]
|
[7] |
Mechlorethamine |
DM0CVXA
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Mechlorethamine. |
Mature T-cell lymphoma [2A90]
|
[7] |
Dacarbazine |
DMNPZL4
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Dacarbazine. |
Melanoma [2C30]
|
[7] |
Ethinyl estradiol |
DMODJ40
|
Moderate |
Altered metabolism of Anakinra due to Ethinyl estradiol alters the formation of CYP450 enzymes. |
Menopausal disorder [GA30]
|
[8] |
Midazolam |
DMXOELT
|
Moderate |
Altered metabolism of Anakinra due to Midazolam alters the formation of CYP450 enzymes. |
Mood/affect symptom [MB24]
|
[6] |
Carfilzomib |
DM48K0X
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Carfilzomib. |
Multiple myeloma [2A83]
|
[7] |
Panobinostat |
DM58WKG
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Panobinostat. |
Multiple myeloma [2A83]
|
[7] |
Lenalidomide |
DM6Q7U4
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Lenalidomide. |
Multiple myeloma [2A83]
|
[7] |
Thalidomide |
DM70BU5
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Thalidomide. |
Multiple myeloma [2A83]
|
[7] |
Selinexor |
DMBD4K3
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Selinexor. |
Multiple myeloma [2A83]
|
[7] |
Belantamab mafodotin |
DMBT3AI
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Belantamab mafodotin. |
Multiple myeloma [2A83]
|
[7] |
Elotuzumab |
DMEYHG9
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Elotuzumab. |
Multiple myeloma [2A83]
|
[7] |
Daratumumab |
DMKCIUZ
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Daratumumab. |
Multiple myeloma [2A83]
|
[7] |
Bortezomib |
DMNO38U
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Bortezomib. |
Multiple myeloma [2A83]
|
[7] |
Melphalan |
DMOLNHF
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Melphalan. |
Multiple myeloma [2A83]
|
[7] |
Tecfidera |
DM2OVDT
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Tecfidera. |
Multiple sclerosis [8A40]
|
[7] |
Siponimod |
DM2R86O
|
Major |
Additive immunosuppressive effects by the combination of Anakinra and Siponimod. |
Multiple sclerosis [8A40]
|
[11] |
Fingolimod |
DM5JVAN
|
Major |
Additive immunosuppressive effects by the combination of Anakinra and Fingolimod. |
Multiple sclerosis [8A40]
|
[12] |
Ocrelizumab |
DMEZ2KH
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Ocrelizumab. |
Multiple sclerosis [8A40]
|
[7] |
Ozanimod |
DMT6AM2
|
Major |
Additive immunosuppressive effects by the combination of Anakinra and Ozanimod. |
Multiple sclerosis [8A40]
|
[6] |
Deflazacort |
DMV0RNS
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Deflazacort. |
Muscular dystrophy [8C70]
|
[7] |
Bexarotene |
DMOBIKY
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Bexarotene. |
Mycosis fungoides [2B01]
|
[7] |
Romidepsin |
DMT5GNL
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Romidepsin. |
Mycosis fungoides [2B01]
|
[7] |
Decitabine |
DMQL8XJ
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Decitabine. |
Myelodysplastic syndrome [2A37]
|
[7] |
Azacitidine |
DMTA5OE
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Azacitidine. |
Myelodysplastic syndrome [2A37]
|
[7] |
Nilotinib |
DM7HXWT
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Nilotinib. |
Myeloproliferative neoplasm [2A20]
|
[7] |
Ruxolitinib |
DM7Q98D
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Ruxolitinib. |
Myeloproliferative neoplasm [2A20]
|
[7] |
Imatinib |
DM7RJXL
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Imatinib. |
Myeloproliferative neoplasm [2A20]
|
[7] |
Dasatinib |
DMJV2EK
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Dasatinib. |
Myeloproliferative neoplasm [2A20]
|
[7] |
Hydroxyurea |
DMOQVU9
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Hydroxyurea. |
Myeloproliferative neoplasm [2A20]
|
[7] |
Omacetaxine mepesuccinate |
DMPU2WX
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Omacetaxine mepesuccinate. |
Myeloproliferative neoplasm [2A20]
|
[7] |
Busulfan |
DMXYJ9C
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Busulfan. |
Myeloproliferative neoplasm [2A20]
|
[7] |
Inebilizumab |
DMI0RHA
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Inebilizumab. |
Nervous system paraneoplastic/autoimmune disorder [8E4A]
|
[7] |
Atezolizumab |
DMMF8U0
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Atezolizumab. |
Non-small cell lung cancer [2C25]
|
[7] |
Olaparib |
DM8QB1D
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Olaparib. |
Ovarian cancer [2C73]
|
[7] |
Carboplatin |
DMG281S
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Carboplatin. |
Ovarian cancer [2C73]
|
[7] |
Altretamine |
DMKLAYG
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Altretamine. |
Ovarian cancer [2C73]
|
[7] |
MK-4827 |
DMLYGH4
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and MK-4827. |
Ovarian cancer [2C73]
|
[7] |
Topotecan |
DMP6G8T
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Topotecan. |
Ovarian cancer [2C73]
|
[7] |
Buprenorphine |
DMPRI8G
|
Moderate |
Altered metabolism of Anakinra due to Buprenorphine alters the formation of CYP450 enzymes. |
Pain [MG30-MG3Z]
|
[6] |
Hydrocodone |
DMQ2JO5
|
Moderate |
Altered metabolism of Anakinra due to Hydrocodone alters the formation of CYP450 enzymes. |
Pain [MG30-MG3Z]
|
[6] |
Streptozocin |
DMOF7AT
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Streptozocin. |
Pancreatic cancer [2C10]
|
[7] |
Levamisole |
DM5EN79
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Levamisole. |
Parasitic infection [1D0Y-1G2Z]
|
[7] |
Pemetrexed |
DMMX2E6
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Pemetrexed. |
Pleural mesothelioma [2C26]
|
[7] |
Prednisone |
DM2HG4X
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Prednisone. |
Postoperative inflammation [1A00-CA43]
|
[7] |
Betamethasone |
DMAHJEF
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Betamethasone. |
Postoperative inflammation [1A00-CA43]
|
[7] |
Hydrocortisone |
DMGEMB7
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Hydrocortisone. |
Postoperative inflammation [1A00-CA43]
|
[7] |
Brodalumab |
DMASDQ6
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Brodalumab. |
Psoriasis [EA90]
|
[7] |
Efalizumab |
DMCKL5V
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Efalizumab. |
Psoriasis [EA90]
|
[13] |
Infliximab |
DMH7OIA
|
Major |
Additive immunosuppressive effects by the combination of Anakinra and Infliximab. |
Psoriasis [EA90]
|
[6] |
Ustekinumab |
DMHTYK3
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Ustekinumab. |
Psoriasis [EA90]
|
[7] |
Tildrakizumab |
DMLW9HG
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Tildrakizumab. |
Psoriasis [EA90]
|
[7] |
Risankizumab |
DMM32GT
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Risankizumab. |
Psoriasis [EA90]
|
[7] |
Ixekizumab |
DMXW92T
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Ixekizumab. |
Psoriasis [EA90]
|
[7] |
Aldesleukin |
DM4YMIS
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Aldesleukin. |
Renal cell carcinoma [2C90]
|
[7] |
Everolimus |
DM8X2EH
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Everolimus. |
Renal cell carcinoma [2C90]
|
[6] |
Temsirolimus |
DMS104F
|
Moderate |
Additive myelosuppressive effects by the combination of Anakinra and Temsirolimus. |
Renal cell carcinoma [2C90]
|
[6] |
Fentanyl |
DM8WAHT
|
Moderate |
Altered metabolism of Anakinra due to Fentanyl alters the formation of CYP450 enzymes. |
Sensation disturbance [MB40]
|
[6] |
Sufentanil |
DMU7YEL
|
Moderate |
Altered metabolism of Anakinra due to Sufentanil alters the formation of CYP450 enzymes. |
Sensation disturbance [MB40]
|
[6] |
Anthrax vaccine |
DM9GSWY
|
Moderate |
Antagonize the effect of Anakinra when combined with Anthrax vaccine. |
Sepsis [1G40-1G41]
|
[14] |
Mogamulizumab |
DMISH0Z
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Mogamulizumab. |
Sezary syndrome [2B02]
|
[7] |
Floxuridine |
DM04LR2
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Floxuridine. |
Solid tumour/cancer [2A00-2F9Z]
|
[7] |
Dactinomycin |
DM2YGNW
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Dactinomycin. |
Solid tumour/cancer [2A00-2F9Z]
|
[7] |
Cyclophosphamide |
DM4O2Z7
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Cyclophosphamide. |
Solid tumour/cancer [2A00-2F9Z]
|
[7] |
Vinblastine |
DM5TVS3
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Vinblastine. |
Solid tumour/cancer [2A00-2F9Z]
|
[6] |
PDX-101 |
DM6OC53
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and PDX-101. |
Solid tumour/cancer [2A00-2F9Z]
|
[7] |
Ifosfamide |
DMCT3I8
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Ifosfamide. |
Solid tumour/cancer [2A00-2F9Z]
|
[7] |
Docetaxel |
DMDI269
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Docetaxel. |
Solid tumour/cancer [2A00-2F9Z]
|
[7] |
Trabectedin |
DMG3Y89
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Trabectedin. |
Solid tumour/cancer [2A00-2F9Z]
|
[7] |
Mitoxantrone |
DMM39BF
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Mitoxantrone. |
Solid tumour/cancer [2A00-2F9Z]
|
[7] |
Etoposide |
DMNH3PG
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Etoposide. |
Solid tumour/cancer [2A00-2F9Z]
|
[7] |
Epirubicin |
DMPDW6T
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Epirubicin. |
Solid tumour/cancer [2A00-2F9Z]
|
[7] |
Prednisolone |
DMQ8FR2
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Prednisolone. |
Solid tumour/cancer [2A00-2F9Z]
|
[7] |
Cisplatin |
DMRHGI9
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Cisplatin. |
Solid tumour/cancer [2A00-2F9Z]
|
[7] |
Gemcitabine |
DMSE3I7
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Gemcitabine. |
Solid tumour/cancer [2A00-2F9Z]
|
[7] |
Norethindrone |
DMTY169
|
Moderate |
Altered metabolism of Anakinra due to Norethindrone alters the formation of CYP450 enzymes. |
Solid tumour/cancer [2A00-2F9Z]
|
[8] |
Fluorouracil |
DMUM7HZ
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Fluorouracil. |
Solid tumour/cancer [2A00-2F9Z]
|
[7] |
Taxol |
DMUOT9V
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Taxol. |
Solid tumour/cancer [2A00-2F9Z]
|
[7] |
Doxorubicin |
DMVP5YE
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Doxorubicin. |
Solid tumour/cancer [2A00-2F9Z]
|
[7] |
Vinorelbine |
DMVXFYE
|
Moderate |
Additive myelosuppressive effects by the combination of Anakinra and Vinorelbine. |
Solid tumour/cancer [2A00-2F9Z]
|
[6] |
Warfarin |
DMJYCVW
|
Moderate |
Altered metabolism of Anakinra due to Warfarin alters the formation of CYP450 enzymes. |
Supraventricular tachyarrhythmia [BC81]
|
[6] |
Pomalidomide |
DMTGBAX
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Pomalidomide. |
Systemic sclerosis [4A42]
|
[7] |
Plicamycin |
DM7C8YV
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Plicamycin. |
Testicular cancer [2C80]
|
[7] |
Apixaban |
DM89JLN
|
Moderate |
Altered metabolism of Anakinra due to Apixaban alters the formation of CYP450 enzymes. |
Thrombosis [DB61-GB90]
|
[6] |
Dicumarol |
DMFQCB1
|
Moderate |
Altered metabolism of Anakinra due to Dicumarol alters the formation of CYP450 enzymes. |
Thrombosis [DB61-GB90]
|
[8] |
Trimetrexate |
DMDEA85
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Trimetrexate. |
Toxoplasmosis [1F57]
|
[7] |
Muromonab |
DM8ANCF
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Muromonab. |
Transplant rejection [NE84]
|
[7] |
Sirolimus |
DMGW1ID
|
Moderate |
Additive myelosuppressive effects by the combination of Anakinra and Sirolimus. |
Transplant rejection [NE84]
|
[6] |
Azathioprine |
DMMZSXQ
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Azathioprine. |
Transplant rejection [NE84]
|
[7] |
Mycophenolate mofetil |
DMPQAGE
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Mycophenolate mofetil. |
Transplant rejection [NE84]
|
[7] |
Basiliximab |
DMWNRZT
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Basiliximab. |
Transplant rejection [NE84]
|
[7] |
Belatacept |
DMXLYQF
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Belatacept. |
Transplant rejection [NE84]
|
[7] |
Tacrolimus |
DMZ7XNQ
|
Moderate |
Additive myelosuppressive effects by the combination of Anakinra and Tacrolimus. |
Transplant rejection [NE84]
|
[6] |
Durvalumab |
DM4PVDY
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Durvalumab. |
Ureteral cancer [2C92]
|
[7] |
Triamcinolone |
DM98IXF
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Triamcinolone. |
Vasomotor/allergic rhinitis [CA08]
|
[7] |
Disopyramide |
DM5SYZP
|
Moderate |
Altered metabolism of Anakinra due to Disopyramide alters the formation of CYP450 enzymes. |
Ventricular tachyarrhythmia [BC71]
|
[6] |
Mexiletine |
DMCTE9R
|
Moderate |
Altered metabolism of Anakinra due to Mexiletine alters the formation of CYP450 enzymes. |
Ventricular tachyarrhythmia [BC71]
|
[6] |
Procainamide |
DMNMXR8
|
Moderate |
Altered metabolism of Anakinra due to Procainamide alters the formation of CYP450 enzymes. |
Ventricular tachyarrhythmia [BC71]
|
[6] |
Propafenone |
DMPIBJK
|
Moderate |
Altered metabolism of Anakinra due to Propafenone alters the formation of CYP450 enzymes. |
Ventricular tachyarrhythmia [BC71]
|
[6] |
Flecainide |
DMSQDLE
|
Moderate |
Altered metabolism of Anakinra due to Flecainide alters the formation of CYP450 enzymes. |
Ventricular tachyarrhythmia [BC71]
|
[6] |
Trifluridine |
DMG2YBD
|
Moderate |
Additive immunosuppressive effects by the combination of Anakinra and Trifluridine. |
Virus infection [1A24-1D9Z]
|
[7] |
----------- |
|
|
|
|
|